# Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer

Source: https://onco.cc/trials/nct01875393/  
OnCo record `nct01875393` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Padeliporfin in Prostate cancer, run by Steba Biotech S.A., completed.

## Summary

Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer is a phase 3 interventional study registered as NCT01875393 by Steba Biotech S.A., with 81 participants recorded, started 2013-05 and reaching its primary completion in 2014-12. Interventions recorded: TOOKAD® Soluble. Conditions recorded: Prostate Cancer.

Linked to the drug Padeliporfin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01875393
- Phase: 3
- Setting: Study of the Efficacy,Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Prostate Cancer
- Sponsor: Steba Biotech S.A.
- Enrolled: 81

## Sources

- ClinicalTrials.gov NCT01875393: https://clinicaltrials.gov/study/NCT01875393

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Padeliporfin](https://onco.cc/drugs/padeliporfin/)
- companies: [Steba Biotech](https://onco.cc/companies/steba-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct01875393.json